Dompé
Dompé Farmaceutici S.p.A /Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalized adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicenter, randomized, double-blinded, placebo controlled, parallel-group phase III trial. (REPAVID-22)